Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
Completed
AstraZeneca
Phase 4
2006-06-01
The purpose of this study is to investigate effect of candesartan based therapy on percent
change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left
ventricular hypertrophy.
Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine
Completed
Novartis
Phase 3
2005-12-01
The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in
hypertensive patients not responding to treatment with ACE inhibitor plus calcium channel
blocker
A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients
Completed
Novartis
Phase 3
2006-08-01
The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in
hypertensive patients not responding to treatment with amlodipine or felodipine alone.
Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina
Completed
Sanofi
Phase 4
2007-06-01
Primary:
- To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients
Secondary:
- To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.
Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
Unknown status
Maastricht University Medical Center
N/A
2008-03-01
In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the
insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II
AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2.
Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular
effects in normotensive control subjects?
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
